Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the increase in polypharmacy for the treatment of pulmonary arterial hypertension will grow the market. Thought leaders agree that multiple pathways contribute to the pathophysiology of pulmonary arterial hypertension and that, ultimately, the best approach to slowing disease progression and improving patient quality of life is to utilize multidrug treatment regimens.

The new Pharmacor study entitled Pulmonary Arterial Hypertension reveals that, although polypharmacy may grow the market, not all patients will benefit from this optimal treatment approach due to cost constraints.

"We believe the use of polypharmacy will be more restricted in Europe compared with other study regions due to general concerns about escalating health care spending in Europe," said Ruth Brown, Ph.D., analyst at Decision Resources. "For example, in the United Kingdom, physicians say that the commission that funds pulmonary arterial hypertension therapy does not promote combination therapy because of the cost burden on the National Health Service. They hope that further studies demonstrating the benefits of such treatment approaches will cause the commission to change its stance."

Revatio -- A Candidate for Combination

The study also finds that the absence of long-term efficacy data for Pfizer's Revatio will result in the agent being used initially in combination with other disease-modifying therapies for pulmonary arterial hypertension. Nevertheless, the low cost of Revatio therapy compared with other agents makes this treatment approach attractive to physicians.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Health Plans Attempt to Rein in Radiology Costs

View Now